Pathogen inactivation technologies for cellular blood components: an update
about
Improving platelet transfusion safety: biomedical and technical considerationsTransfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in MicePrevention of transfusion-transmitted Zika virus in French Polynesia, nucleic acid testing versus pathogen inactivationThe European Hematology Association Roadmap for European Hematology Research: a consensus documentZika virus and inherited bleeding disordersTowards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countriesTransfusion practices and infectious risks.Pathogen reduction technologies: The pros and cons for platelet transfusion.Mirasol pathogen reduction technology treatment of human whole blood does not induce acute lung injury in mice.Treatment of Ebola virus infection with antibodies from reconvalescent donors.Occult hepatitis B virus infection and blood transfusionTransfusion-transmitted CMV infection - current knowledge and future perspectives.Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.Description of 15 DNA-positive and antibody-negative "window-period" blood donations identified during prospective screening for Babesia microti.Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma.In vitro Quality of Platelets with Low Plasma Carryover Treated with Ultraviolet C Light for Pathogen Inactivation.Pathogen reduction through additive-free short-wave UV light irradiation retains the optimal efficacy of human platelet lysate for the expansion of human bone marrow mesenchymal stem cells.Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation.Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-κB Activation.Assessment of nucleic acid modification induced by amotosalen and ultraviolet A light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNA.Altered timing of riboflavin and ultraviolet light pathogen inactivation improves platelet in vitro quality.Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: A systematic review with regional discussion.Japanese Encephalitis Virus Transmitted Via Blood Transfusion, Hong Kong, China.Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet A light.Parvovirus B19: What Is the Relevance in Transfusion Medicine?Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols.Real-time measurement of platelet shape change by light scattering under riboflavin and ultraviolet light treatment.Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment.Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution.Evaluation of positive and false-positive results in syphilis screening of blood donors in Rio de Janeiro, Brazil.Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets.Bacterial contamination of platelets for transfusion: strategies for preventionBudget impact of implementing platelet pathogen reduction into the Italian blood transfusion system
P2860
Q26775408-FAD69225-1F7E-4DAA-9CB4-E616CAFCC340Q27302578-53525A8D-4EC1-40AF-8797-3727D0614750Q28733459-E96858DA-E2A8-45DA-834F-88D63E3515F9Q28830861-A26727AC-D6EC-44E3-B92C-2326A4E40FC9Q28950432-56EF5F1A-A93A-4C75-89A1-4BCDEF32059BQ29994506-A30E80A7-916F-4C77-B2E3-CA6687870141Q31056026-C45B0A83-B2C9-49C7-98E3-6FDC01061EECQ33441980-E53F27FE-170B-4DDD-B6A1-C94EEB87932DQ33751938-ABFABDD9-52BE-48DA-A48F-7EF965E8A45DQ35130375-0F34AFDE-6945-4889-9DEC-797689163246Q35237335-7441FB9E-1449-4CAD-908F-11F398CAFD7DQ38667640-CC7A4D40-EB70-4410-AC5F-17CA748DCE7FQ38794017-53200E54-9472-4A07-B360-5F2D35C636DAQ38814836-AF9BD652-6254-4A42-9F1F-F35F0CDC1C97Q39148796-40310B13-70D5-4624-9090-E758E06710B1Q39611196-45E5E307-4FA0-4F9A-B3A0-2C3DF3430BB7Q40099637-8811A042-B484-44AA-8A81-2A8F795C3319Q40611312-8707880F-1963-49D5-BF0D-EC1D3249D9B2Q40713949-C81EEE7D-E57A-4C3C-A520-EB256A31BDC1Q40962292-C007CAD2-40E9-4D62-93AC-2269434207E0Q41970183-D73F4A95-3119-4AEC-883C-F2D801E32655Q42015397-5131EBB5-7898-4464-BCDE-3FFFD33C2BA5Q43047360-AEBFF802-4E6C-440D-B5CD-1D18381C3FEAQ47312219-23A1087A-954A-4730-A534-08866AF9BD07Q49416500-6251A6DA-A5C5-44D4-B79A-25322714E86AQ50215215-504E15D5-520C-449B-A25B-EBC9CCDA691DQ50278941-B9F2009B-8F80-4A8E-831C-BC82ECDC77A6Q53091893-E9FD0656-62DC-4808-B9FF-4FD1499AED12Q53251240-877A1524-559A-4E02-87BB-0AFB7E2AE304Q54430124-773FCF1A-D0D8-41AB-AED5-28AB14DE8F9FQ54977038-D09F0D74-3849-4559-B3BC-E36B4C63D8DDQ58110468-19A71148-5734-4AC1-ACCC-8AD728088A8CQ58701334-27BE38A6-F97A-42FC-A0CD-B5B14C997C6B
P2860
Pathogen inactivation technologies for cellular blood components: an update
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Pathogen inactivation technologies for cellular blood components: an update
@ast
Pathogen inactivation technologies for cellular blood components: an update
@en
Pathogen inactivation technologies for cellular blood components: an update
@nl
type
label
Pathogen inactivation technologies for cellular blood components: an update
@ast
Pathogen inactivation technologies for cellular blood components: an update
@en
Pathogen inactivation technologies for cellular blood components: an update
@nl
prefLabel
Pathogen inactivation technologies for cellular blood components: an update
@ast
Pathogen inactivation technologies for cellular blood components: an update
@en
Pathogen inactivation technologies for cellular blood components: an update
@nl
P2860
P356
P1476
Pathogen inactivation technologies for cellular blood components: an update
@en
P2093
Peter Schlenke
P2860
P304
P356
10.1159/000365646
P407
P577
2014-07-01T00:00:00Z